000285733 001__ 285733
000285733 005__ 20260320145541.0
000285733 0247_ $$2doi$$a10.1186/s41824-026-00294-8
000285733 0247_ $$2pmid$$apmid:41857168
000285733 037__ $$aDZNE-2026-00290
000285733 041__ $$aEnglish
000285733 082__ $$a610
000285733 1001_ $$00000-0002-2055-2764$$aHesse, Swen$$b0
000285733 245__ $$aAn MSA-P patient presenting with preserved glucose metabolism in the putamen, cerebellar hypometabolism and pronounced loss of presynaptic dopamine transporter in the striatum.
000285733 260__ $$a[Cham]$$bSpringer International Publishing$$c2026
000285733 3367_ $$2DRIVER$$aarticle
000285733 3367_ $$2DataCite$$aOutput Types/Journal article
000285733 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1774014822_12445
000285733 3367_ $$2BibTeX$$aARTICLE
000285733 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285733 3367_ $$00$$2EndNote$$aJournal Article
000285733 520__ $$aPositron emission tomography (PET) of the brain using [18F]fluorodeoxyglucose (FDG) is becoming increasingly important for the diagnosis and differential diagnosis of atypical parkinsonian syndrome such as multiple system atrophy (MSA), which is characterized by hypometabolism of the putamen, pons, and cerebellum. We report on a patient with clinically established MSA based on a rapidly progressive, poorly levodopa-responsive parkinsonian syndrome, multidomain autonomic failure, and imaging findings where hereditary spastic paraplegia was discussed as a differential diagnosis. PET images revealed a well-preserved glucose metabolism in the striatum, specifically in the putamen, while metabolism in the cerebellum was significantly reduced. This pattern of glucose metabolism might indicate a distinct subtype of synucleinopathy as proven by seed-amplification assay and should be taken into account when diagnosing patients with MSA.
000285733 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285733 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285733 650_7 $$2Other$$aDopamine transporter
000285733 650_7 $$2Other$$aFDG
000285733 650_7 $$2Other$$aMSA
000285733 650_7 $$2Other$$aMultiple system atrophy
000285733 650_7 $$2Other$$aPET
000285733 650_7 $$2Other$$aParkinsonian syndrome
000285733 650_7 $$2Other$$aPutamen
000285733 650_7 $$2Other$$aSPECT
000285733 650_7 $$2Other$$aSPG
000285733 650_7 $$2Other$$a[18F]fluorodeoxyglucose
000285733 7001_ $$aSchiefer, Manja$$b1
000285733 7001_ $$aTiepolt, Solveig$$b2
000285733 7001_ $$aProchnow, Dorit$$b3
000285733 7001_ $$aMämecke, Larissa$$b4
000285733 7001_ $$aHoffmann, Frank$$b5
000285733 7001_ $$0P:(DE-2719)9000748$$aSchniewind, Inaki$$b6
000285733 7001_ $$0P:(DE-2719)2814810$$aSabri, Osama$$b7$$udzne
000285733 7001_ $$0P:(DE-2719)2814178$$aFalkenburger, Björn$$b8$$udzne
000285733 7001_ $$aBrock, Sebastian$$b9
000285733 773__ $$0PERI:(DE-600)3181214-4$$a10.1186/s41824-026-00294-8$$gVol. 10, no. 1, p. 10$$n1$$p10$$tEJNMMI reports$$v10$$x3005-074X$$y2026
000285733 8564_ $$uhttps://pub.dzne.de/record/285733/files/DZNE-2026-00290.pdf$$yRestricted
000285733 8564_ $$uhttps://pub.dzne.de/record/285733/files/DZNE-2026-00290.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285733 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000748$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000285733 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2814810$$aExternal Institute$$b7$$kExtern
000285733 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814178$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000285733 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285733 9201_ $$0I:(DE-2719)1710012$$kAG Falkenburger$$lTranslational Parkinson Research$$x0
000285733 980__ $$ajournal
000285733 980__ $$aEDITORS
000285733 980__ $$aVDBINPRINT
000285733 980__ $$aI:(DE-2719)1710012
000285733 980__ $$aUNRESTRICTED